v3.26.3
REVENUE AND COST OF SALES (Tables)
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Net product sales:
   EXPAREL$142,510 $139,902 $433,607 $419,348 
   ZILRETTA29,760 28,982 89,175 83,654 
   iovera° (1)
1,982 6,465 14,964 17,176 
   Bupivacaine liposome injectable suspension1,184 2,691 5,559 5,803 
      Total net product sales$175,436 $178,040 $543,305 $525,981 
(1) In June 2026, the Company entered into the Purchase Agreement with Zimmer to divest iovera°. The Divestiture was completed on July 31, 2026, after which the Company no longer recognizes revenue associated with iovera°. For more information, see Note 3, iovera° Divestiture.
Schedule of disaggregation of cost of goods and service sold
The following table represents disaggregated cost of goods sold and cost of service in the periods presented as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Cost of goods sold (1)
$36,374 $34,278 $116,951 $109,450 
Cost of service859 — 859 — 
Total cost of sales (1)
$37,233 $34,278 $117,810 $109,450 
(1) Exclusive of amortization of acquired intangible assets